13F-HR: Regeneron Pharmaceuticals Q1 2026 13F Holdings Update

Regeneron Pharmaceuticals discloses its equity investment portfolio as of March 31, 2026, featuring holdings in Adicet Bio and Intellia Therapeutics.

Summary

• Regeneron Pharmaceuticals reported total equity holdings valued at approximately $47.88 million as of March 31, 2026.
• The portfolio consists of two primary equity positions in the biotechnology sector.
• The filing confirms sole voting and investment discretion over all reported shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure of existing equity positions with no material change in corporate strategy.

Positives

• Maintains strategic investments in specialized biotechnology firms.
• Clear and transparent reporting of equity positions with full voting authority.

Negatives

• Limited diversification with only two equity holdings reported.
• High concentration risk in the biotechnology sector.

Risks

• Market volatility inherent in the biotechnology sector.
• Concentration risk due to the small number of holdings.
• Potential for significant valuation fluctuations in clinical-stage biotech companies.

Future Outlook

The filing does not provide forward-looking statements regarding investment strategy or future portfolio changes.

Management Comments

• Leonard Brooks, Senior Vice President and Treasurer, confirmed the accuracy and completeness of the reported holdings.

Industry Context

StockSavvy.ai notes that Regeneron's 13F reflects a focused investment strategy typical of large-cap biopharma companies, which often take minority stakes in smaller, innovative biotech firms to monitor or potentially partner on emerging therapeutic platforms like gene editing.

Comparison to Industry Standards

• The portfolio size is relatively small compared to the total market capitalization of Regeneron, indicating these are strategic rather than core treasury investments.
• The selection of Intellia Therapeutics and Adicet Bio aligns with industry trends of large-cap pharma investing in CRISPR/Cas9 and cell therapy developers.

Stakeholder Impact

• Shareholders should note the continued strategic interest in Intellia and Adicet as indicators of Regeneron's R&D focus areas.

Next Steps

• Submission of the next quarterly 13F report for the period ending June 30, 2026.

Key Dates

Keywords

Regeneron, 13F, Biotechnology, Investment Portfolio, Intellia Therapeutics, Adicet Bio